Sodium–glucose cotransporter-2 inhibitors and clinical outcomes in patients with hypertrophic cardiomyopathy and diabetes: A population-based cohort study DOI Creative Commons
Mi‐Hyang Jung, Jung Sun Cho, So‐Young Lee

et al.

European Journal of Preventive Cardiology, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 22, 2024

Hypertrophic cardiomyopathy (HCM) is associated with a significant risk of arrhythmia and heart failure (HF), yet treatment options for patients HCM have remained limited. We aimed to investigate the relationship between sodium-glucose cotransporter-2 inhibitor (SGLT2i) use clinical outcomes among concurrent diabetes in real-world settings.

Language: Английский

Empagliflozin prevents heart failure through inhibition of the NHE1-NO pathway, independent of SGLT2 DOI Creative Commons
Sha Chen, Qian Wang,

Diane Bakker

et al.

Basic Research in Cardiology, Journal Year: 2024, Volume and Issue: 119(5), P. 751 - 772

Published: July 24, 2024

Sodium glucose cotransporter 2 inhibitors (SGLT2i) constitute the only medication class that consistently prevents or attenuates human heart failure (HF) independent of ejection fraction. We have suggested earlier protective mechanisms SGLT2i Empagliflozin (EMPA) are mediated through reductions in sodium hydrogen exchanger 1 (NHE1)-nitric oxide (NO) pathway, SGLT2. Here, we examined role SGLT2, NHE1 and NO a murine TAC/DOCA model HF. SGLT2 knockout mice showed attenuated systolic dysfunction without having an effect on other signs EMPA protected against diastolic dysfunction, hypertrophy, fibrosis, increased Nppa/Nppb mRNA expression lung/liver edema. In addition, prevented increases oxidative stress, calcium calcium/calmodulin-dependent protein kinase II activation to equal degree WT KO animals. particular, while activity was isolated cardiomyocytes from untreated HF, treatment this. Since is not required for effects EMPA, pathway between further explored vivo with specific NHE1-inhibitor Cariporide mimicked protection by additional EMPA. On hand, inhibition NOS L-NAME deteriorated HF conclusion, data support beneficial NHE1-NO TAC/DOCA-induced inhibition.

Language: Английский

Citations

9
Cardiac MRI Strain as an Early Indicator of Myocardial Dysfunction in Hypertrophic Cardiomyopathy DOI Open Access
Siqin Liu, Oumaima Laghzali,

Shahriar Shalikar

et al.

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(4), P. 1407 - 1407

Published: Feb. 7, 2025

Hypertrophic cardiomyopathy (HCM) is often characterized by augmented cardiac contractility, which frequently remains undetectable in its early stages. Emerging evidence suggests that hypercontractility linked to mitochondrial defects develop HCM progression. However, imaging markers for identifying these alterations myocardial function are lacking. We used magnetic resonance feature tracking (CMR-FT) assess strain a Mybpc3-knockin (KI) mouse model mimicked human HCM. While homozygous (HOM) mice exhibited hypertrophy, heterozygous (HET) represented an early, asymptomatic stage of To explore contributions hypercontractility, we evaluated integrity via scanning electron microscopy (SEM) and correlated findings with abnormalities. Young HET female, but not male significant torsion abnormalities (p = 0.02), reduced left ventricular global longitudinal (LVGLS, p 0.009), impaired right (RVGLS, 0.035) compared the controls. Strain strongly morphological alterations, including changes volume area distribution (R > 0.7). Abnormal patterns, GLS, serve as closely associated underlying dysfunction. The Mybpc3-KI provides important insights into initial stages progression, highlighting sex-specific differences enhance diagnosis therapeutic strategies.

Language: Английский

Citations

1
Single-nucleus RNA sequencing identifies cell-type–specific effects of sodium-glucose co-transporter 2 inhibitors in human myocardial slices DOI Creative Commons
Kevin Schmidt, Maximilian Fuchs, Natalie Weber

et al.

European Heart Journal, Journal Year: 2024, Volume and Issue: 45(35), P. 3292 - 3295

Published: July 31, 2024

Language: Английский

Citations

5
Advances in the study and treatment of genetic cardiomyopathies DOI
Victoria N. Parikh, Sharlene M. Day,

Neal K. Lakdawala

et al.

Cell, Journal Year: 2025, Volume and Issue: 188(4), P. 901 - 918

Published: Feb. 1, 2025

Language: Английский

Citations

0
Characteristics and pharmacological responsiveness in hiPSC models of inherited cardiomyopathy DOI Creative Commons

Merel Gerritse,

Willem B. van Ham, Chris Denning

et al.

Pharmacology & Therapeutics, Journal Year: 2025, Volume and Issue: unknown, P. 108845 - 108845

Published: April 1, 2025

Inherited cardiomyopathies are a major cause of heart failure in all age groups, often with an onset adolescence or early adult life. More than thousand variants approximately one hundred genes associated cardiomyopathies. Interestingly, many genetic display overlapping phenotypical defects patients, despite the diversity initial pathogenic variants. Understanding how underlying pathophysiology leads to these phenotypes, will improve insights into patient's disease course and creates opportunity for conceiving treatment strategies. Moreover, therapeutic strategies can be used treat multiple based on shared phenotypes. Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) offer reliable, high-throughput models studying molecular cellular characteristics hereditary hiPSC-CMs produced relatively easily, either by directly originating them from introducing patient-specific healthy lines. This review evaluates 90 studies 24 cardiomyopathy-associated systematically summarises morphological functional phenotypes observed hiPSC-CMs. Additionally, applied cardiomyopathic compiled scored effectiveness. Multiple phenotypic were identified different variants, whereas certain only specific Based findings, common mechanisms, prospects, considerations future research discussed aim clinical translation patients.

Language: Английский

Citations

0
Advancements in the Diagnosis and Treatment of Hypertrophic Cardiomyopathy DOI

妞妞 牟

Advances in Clinical Medicine, Journal Year: 2025, Volume and Issue: 15(03), P. 108 - 115

Published: Jan. 1, 2025

Language: Английский

Citations

0
Dapagliflozin and atrial fibrillation: elevated dosing to achieve class I antiarrhythmic effects? DOI Creative Commons
Torsten Christ, Edzard Schwedhelm, Thomas Eschenhagen

et al.

Basic Research in Cardiology, Journal Year: 2024, Volume and Issue: 119(3), P. 505 - 507

Published: April 3, 2024

Language: Английский

Citations

1
Obese or lean: Whom to prescribe sodium–glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction? DOI

Kseniya Halavina,

Philipp E. Bartko, Christian Nitsche

et al.

European Journal of Heart Failure, Journal Year: 2024, Volume and Issue: 26(4), P. 910 - 911

Published: April 1, 2024

Language: Английский

Citations

0
Sodium–glucose cotransporter-2 inhibitors and clinical outcomes in patients with hypertrophic cardiomyopathy and diabetes: A population-based cohort study DOI Creative Commons
Mi‐Hyang Jung, Jung Sun Cho, So‐Young Lee

et al.

European Journal of Preventive Cardiology, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 22, 2024

Hypertrophic cardiomyopathy (HCM) is associated with a significant risk of arrhythmia and heart failure (HF), yet treatment options for patients HCM have remained limited. We aimed to investigate the relationship between sodium-glucose cotransporter-2 inhibitor (SGLT2i) use clinical outcomes among concurrent diabetes in real-world settings.

Language: Английский

Citations

0